TG Therapeutics (TGTX)
(Real Time Quote from BATS)
$24.14 USD
-0.51 (-2.07%)
Updated Sep 23, 2024 09:56 AM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for TG Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 234 | 3 | 7 | 0 | 0 |
Cost Of Goods | 14 | 0 | 1 | 0 | 0 |
Gross Profit | 220 | 3 | 6 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 199 | 195 | 351 | 274 | 169 |
Income After Depreciation & Amortization | 21 | -193 | -345 | -274 | -169 |
Non-Operating Income | 5 | 5 | 2 | 1 | 1 |
Interest Expense | 13 | 10 | 6 | 6 | 5 |
Pretax Income | 13 | -198 | -348 | -279 | -173 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 13 | -198 | -348 | -279 | -173 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 13 | -198 | -348 | -279 | -173 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 21 | -191 | -343 | -273 | -168 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 2 | 1 | 1 |
Income After Depreciation & Amortization | 21 | -193 | -345 | -274 | -169 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 148.51 | 135.41 | 132.22 | 115.33 | 88.37 |
Diluted EPS Before Non-Recurring Items | 0.09 | -1.46 | -2.63 | -2.42 | -1.83 |
Diluted Net EPS (GAAP) | 0.09 | -1.46 | -2.63 | -2.42 | -1.96 |
Fiscal Year end for TG Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 73.47 | 63.47 | 43.97 | 165.82 | 16.07 |
Cost Of Goods | 8.30 | 5.44 | 7.85 | 3.51 | 1.91 |
Gross Profit | 65.16 | 58.03 | 36.12 | 162.31 | 14.16 |
SG&A, R&D, and Dept/Amort Expenses | 56.35 | 67.30 | 48.60 | 47.52 | 58.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 8.81 | -9.27 | -12.48 | 114.79 | -44.68 |
Non-Operating Income | 1.71 | 0.88 | 0.89 | 2.86 | 0.69 |
Interest Expense | 3.98 | 2.29 | 2.43 | 3.71 | 3.63 |
Pretax Income | 6.55 | -10.68 | -14.03 | 113.93 | -47.61 |
Income Taxes | -0.33 | 0.03 | 0.39 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 6.88 | -10.71 | -14.42 | 113.93 | -47.61 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 6.88 | -10.71 | -14.42 | 113.93 | -47.61 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 159.42 | 146.21 | 156.09 | 155.87 | 141.50 |
Diluted EPS Before Non-Recurring Items | 0.04 | -0.07 | -0.09 | 0.73 | -0.34 |
Diluted Net EPS (GAAP) | 0.04 | -0.07 | -0.02 | 0.73 | -0.34 |